Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

NCT04537442 is registered in ClinicalTrials.gov with Beijing Immunochina Medical Science & Technology Co., Ltd. as lead sponsor.

NCT NCT04537442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04537442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
September 3, 2020
Completion date
March 2, 2023
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma